company background image
VCEL logo

Vericel NasdaqGM:VCEL Stock Report

Last Price

US$52.02

Market Cap

US$2.5b

7D

11.4%

1Y

84.3%

Updated

28 Mar, 2024

Data

Company Financials +

VCEL Stock Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.

VCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for VCEL from our risk checks.

Vericel Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vericel
Historical stock prices
Current Share PriceUS$52.02
52 Week HighUS$52.50
52 Week LowUS$28.02
Beta1.7
1 Month Change8.38%
3 Month Change46.08%
1 Year Change84.27%
3 Year Change-2.22%
5 Year Change200.69%
Change since IPO-95.36%

Recent News & Updates

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Recent updates

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Oct 10

Vericel Q2 2022 Earnings Preview

Aug 02

Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Apr 19
Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Vericel - A Disruptive Business With Years Of Growth Remaining

Apr 12

Vericel: In The Middle Of Difficulty Is An Opportunity

Dec 31

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09
Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Vericel: A Leader In Cell-Based Therapy

May 26

Vericel Q1 2021 Earnings Preview

May 04

Shareholder Returns

VCELUS BiotechsUS Market
7D11.4%0.9%0.2%
1Y84.3%11.0%28.1%

Return vs Industry: VCEL exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: VCEL exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is VCEL's price volatile compared to industry and market?
VCEL volatility
VCEL Average Weekly Movement5.9%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: VCEL's share price has been volatile over the past 3 months.

Volatility Over Time: VCEL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989314Nick Colangelohttps://vcel.com

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation Fundamentals Summary

How do Vericel's earnings and revenue compare to its market cap?
VCEL fundamental statistics
Market capUS$2.53b
Earnings (TTM)-US$3.18m
Revenue (TTM)US$197.52m

12.7x

P/S Ratio

-789.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VCEL income statement (TTM)
RevenueUS$197.52m
Cost of RevenueUS$61.94m
Gross ProfitUS$135.58m
Other ExpensesUS$138.76m
Earnings-US$3.18m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.066
Gross Margin68.64%
Net Profit Margin-1.61%
Debt/Equity Ratio0%

How did VCEL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.